Особенности вязко-эластических свойств сгустка крови и проявления геморрагического синдрома при тромбоцитопении у онкогематологических больных:

Summary. Background. Thrombocytopenia is a frequent complication of hemoblastosis that causes hemorrhagic syndrome. The threshold of peripheral blood platelet count for transfusion of platelet concentrate is discussed. Thromboelastography (TEG) can be considered as additional prognostic method for bleeding risk assessment in thrombocytopenic patients with leukemia. Objectives: to study changes in the viscoelastic properties of blood clot in hemoblastosis patients with thrombocytopenia less than 50×109/L and their relationship with the manifestations of hemorrhagic syndrome. Patients/Methods. The study included 84 hemoblastosis patients — 54 (64%) men и 30 (36%) women with thrombocytopenia less than 50×109/L, median age — 54 years. All patients are divided into 2 groups according to the platelet count: Group 1 — 25–50×109/L, Group 2 — less than 25×109/L. Peripheral blood counts, TEG and coagulogram parameters were evaluated in both groups. Manifestations of hemorrhagic syndrome were assessed according to the WHO bleeding scale and Common terminology criteria for adverse events of the National Cancer Institute (USA). Results. Hypocoagulation according TEG in Group 1 was found in 46% of cases, in Group 2 — in 75%. Significant intergroup differences in TEG parameters were obtained only in maximum amplitude. Hemorrhagic syndrome in Group 1 diagnosed in 6 (14%) patients, in Group 2 — in 14 (35%). There was no dependence of hemorrhagic syndrome frequency on the severity of thrombocytopenia (β = 0.016; p = 0.92). The combination of thrombocytopenia and hypocoagulation according TEG manifested as a hemorrhagic syndrome 3.3 times more often than without hypocoagulation (RR = 3.3; 95% CI = 1.20–9.05). In some cases, TEG-based transfusion tactics allowed to avoid unnecessary platelet concentrate transfusion during invasive procedures in patients with thrombocytopenia less than 25×109/L. Conclusions. Severity of platelet depletion is not accuracy predictor for hemorrhagic events. Use of TEG in patients with thrombocytopenia allows to optimize the transfusion tactics and to avoid unnecessary platelet concentrate transfusions. The combination of severe thrombocytopenia with hypocoagulation according TEG serves as indication for prophylactic platelet concentrate transfusion. References Callow C.R., Swindell R., Randall W., Chopra R.The frequency of bleeding complications in patients with haematological malignancy following the introduction of a stringent prophylactic platelet transfusion policy. Br J Haematol. 2002;118:677–82. DOI: 0.1046/j.1365–2141.2002.03616.x. Tiberghien P., Follea G., Muller J.Y. Platelet transfusions in acute leukemia. N Engl J Med. 2016;375(1):96–7. DOI: 10.1056/NEJMc1515066. Gaydos L. A., Freireich E. J., Mantel N. The quantitative relation between platelet count and hemorrhage in patients with acute leukemia. N Engl J Med. 1962;266:905–9. DOI: 10.1056/NEJM196205032661802. Gmur J., Burger J., Schanz U. et al. Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemia. Lancet. 1991;338(8777):1223–6. DOI: 10.1016/0140–6736(91)92098‐m. British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines for the use of platelet transfusions. Br J Haematol. 2003;122(1):10–23. DOI: 10.1046/j.1365–2141.2003.04468.x. Kaufman R.M., Djulbegovic B., Gernsheimer T. et al; AABB. Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med. 2015;162(3):205–13. DOI: 10.7326/M14–1589. Kasivisvanathan R., Koutra M., Rooms M. et al. Thromboelastography (TEG®) compared with total platelet count in thrombocytopenia haematological malignancy patients with bleeding: a pilot observational study. Transfus Med. 2015;25(5):307–12. DOI: 10.1111/tme.12221. Slichter S.J., Kaufman R.M., Assmann S.F. et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med. 2010;362(7):600–13. DOI: 10.1056/NEJMoa0904084. Bernstein S.H., Nademanee A.P., Vose J.M. et al. A multicenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic stem cell transplantation. Blood. 1998;91(9):3509–17. Avvisati G., Tirindelli M.C., Annibali O. Thrombocytopenia and hemorrhagic risk in cancer patients. Crit Rev Oncol Hematol. 2003;48(Suppl): S13–6. DOI: 10.1016/j.critrevonc.2003.04.001. Bulanov A. Yu., Gorodetsky V.M., Shcherbakova O.V. et al. Thromboelastographic evaluation of the hemostasis system and efficiency of its correction before surgical interventions in hematological patients. Gematologiya i transfuziologiya. 2012;57(5):36–42. (In Russ.). FahrendorffM.,OliveriR.S.,JohanssonP.I.Theuseofviscoelastic haemostatic assays in goal‐directing treatment with allogeneic blood products — A systematic review and meta‐analysis. Scand The authors declare no conflict of interests. The study was not sponsored. J Trauma Resusc Emerg Med. 2017;25(1):39. DOI: 10.1186/s13049–017–0378–9. Stanworth S.J., Estcourt L.J., Powter G. et al. A no‐prophylaxis platelet‐transfusion strategy for hematologic cancers. N Engl J Med. 2013;368(19):1771–80. DOI: 10.1056/NEJMoa1212772. Common terminology criteria for adverse events (CTCAE) version 4.0. Bethesda, MD: NCI, NIH publication 09–5410. National Cancer Institute, 2009. 79 pp. Available at: https://evs.nci.nih.gov/ftp1/ CTCAE / CTCAE_4.03 / Archive/CTCAE_4.0_2009–05–29_QuickReference_8.5x11.pdf. Vinholt P.J., Alnor A., Nybo M., Hvas A.M. Prediction of bleeding and prophylactic platelet transfusions in cancer patients with thrombocytopenia. Platelets. 2016;27(6):547–54. DOI: 10.3109/0 9537104.2015.1131814. Gatt A., Bonello F., Buttigieg R. et al. Flow cytometry and thromboelastography to assess platelet counts and coagulation in patients with haematological malignancies. Blood Transfus. 2014;12(4):479– 84. DOI: 10.2450/2014.0259–13. Crighton G.L., Estcourt L.J., Wood E.M. et al. A therapeutic‐only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation. Cochrane Database Syst Rev. 2015;(9):CD010981. DOI: 10.1002/14651858. CD010981.pub2. Estcourt L.J., Stanworth S.J., Doree C. et al. Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation. Cochrane Database Syst Rev. 2015;(11): CD010983. DOI: 10.1002/14651858.CD010983.pub2. Opheim E.N., Apelseth T.O., Stanworth S.J. et al. Thromboelastography may predict risk of grade 2 bleeding in thrombocytopenic patients. Vox Sang. 2017;112(6):578–85. DOI: 10.1111/vox.12544. Franchini M., Frattini F., Crestani S., Bonfanti C. Bleeding complications in patients with hematologic malignancies. Semin Thromb Hemost. 2013;39(1):94–100. DOI: 10.1055/s‐0032–1331154. Larsen A.M., Leinoe E.B., Johansson P.I. et al. High syndecan‐1 levels in acute myeloid leukemia are associated with bleeding, thrombocytopathy, endothelial cell damage, and leukocytosis. Leuk Res. 2013;37(7):777–83. DOI: 10.1016/j.leukres.2013.02.015. Dias J.D., Sauaia A., Achneck H.E. et al. Thromboelastographyguided therapy improves patient blood management and certain clinical outcomes in elective cardiac and liver surgery and emergency resuscitation: A systematic review and analysis. J Thromb Haemost. 2019;17(6):984–94. DOI: 10.1111/jth.14447. De Pietri L., Bianchini M., Montalti R. et al. Thrombelastographyguided blood product use before invasive procedures in cirrhosis with severe coagulopathy: A randomized, controlled trial. Hepa- tology. 2016;63(2):566–73. DOI: 10.1002/hep.28148.